louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06331221: Effects of Different Concentric and Eccentric Muscle Fatigue Protocols on the Knee Joint Position Sense
Official title: Effects of Different Concentric and Eccentric Muscle Fatigue Protocols on the Knee Joint Position Sense: a Randomized Controlled Crossover Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Muscle Fatigue
Knee
Joint Position Sense
Proprioception
Lead sponsor: Universidade do Porto
Sponsor class: OTHER
First posted: 2024-03-26
Enrollment: 22
Sex: MALE
Minimum age (years): 18
Maximum age (years): 30
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The aim of this study was to investigate the effects of different concentric and eccentric muscle fatigue protocols on the knee joint position sense of healthy individuals.

Detailed description: A randomized controlled crossover trial will be conducted at a biomechanics laboratory with healthy males. All participants will perform with a washout period of 1 week: a control condition (5-minute rest) and 4 local muscle fatigue protocols (concentric of quadriceps; concentric of hamstrings; eccentric of quadriceps; eccentric of hamstrings) in an isokinetic dynamometer at 30º/s. Three maximum voluntary isometric contractions (MVIC) of quadriceps and hamstrings will also be assessed in the beginning of all conditions.

Knee joint position sense will be assessed before and immediately after the fatigue protocols/control condition, through active concentric and eccentric positionings/repositionings, in sitting and prone positions, to a target range of 45º of knee flexion in an isokinetic dynamometer. Surface electromyography electrodes will also be placed on the vastus lateralis and biceps femoris during all procedures.

Eligibility criteria: Inclusion Criteria:

* males aged between 18 and 30 years;
* without current or previous knee pathology or surgery;
* with a low or moderate physical activity level, according to the International Physical Activity Questionnaire;
* normal Body Mass Index (under 24.9 kg/m2), according to the World Health Organization.

Exclusion Criteria:

* those with cardiorespiratory, neurological or vestibular pathologies;
* with positive knee integrity tests (anterior drawer, Lachman's test, posterior drawer; valgus and varus stress testes); and
* those taking any medication that can affect motor control (sedatives, anxiolytics, antibiotics, analgesics, NSAIDs or myorelaxants).

Primary outcomes:
measure: Absolute angular error
timeFrame: Change from Baseline (Before) to Immediately after interventions or control (After)
measure: Relative angular error
timeFrame: Change from Baseline (Before) to Immediately after interventions or control (After)
measure: Variable angular error
timeFrame: Change from Baseline (Before) to Immediately after interventions or control (After)
Secondary outcomes:
Other outcomes:
Locations:
city: Porto
country: Portugal
facility: Faculdade de Desporto, Universidade do Porto
Study officials:
References:
Clinical trial NCT04790721: Relationship Between Academic Achievement, Musculoskeletal System, Quality of Life and Technology Addiction
Official title: How Much Does Technology Addiction in Youth Affect Academic Achievement, Musculoskeletal System and Quality of Life?
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Technology Addiction
Musculoskeletal System
Quality of Life
Youth
Lead sponsor: Pamukkale University
Sponsor class: OTHER
First posted: 2021-03-10
Enrollment: 473
Sex: ALL
Minimum age (years): 20
Maximum age (years): 30
Standard ages: ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Our study is important in terms of determining the effects of not only smartphone use but also computer use addiction on health. For this reason, our study was conducted to investigate the effect of technology addiction on academic achievement, musculoskeletal system and quality of life on behalf of young people.

Brief summary: The increasing use of technological devices such as mobile phones and computers has become indispensable elements of daily life. Especially students are one of the groups that use communication tools most with the developing technology. This study was conducted to investigate the effect of technology addiction on academic achievement, musculoskeletal system and quality of life in young people.


Eligibility criteria: Inclusion Criteria:

* Individuals between the ages of 20-30, using smartphones and/or computers were included in the study.

Exclusion Criteria:

* Individuals who did not meet the inclusion criteria and had a physical-psycho-social condition that could affect the study were excluded from the study.

Primary outcomes:
measure: Smartphone Addiction Scale-Short Form
timeFrame: 5 minutes
measure: Young Internet Addiction Test Short Form
timeFrame: 5 minutes
measure: Cornell Musculoskeletal Discomfort Questionnaire
timeFrame: 5 minutes
measure: Short Form-36
timeFrame: 5 minutes
measure: Meaning of Life Questionnaire
timeFrame: 2 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Denizli
country: Turkey
facility: Pamukkale University
Study officials:
References:
Clinical trial NCT06305702: Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer
Official title: Multicenter Real-world Clinical Study of Inetetamab-based Therapy in HER2-positive Metastatic Breast Cancer
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: HER2-positive Metastatic Breast Cancer
Lead sponsor: Liaoning Cancer Hospital & Institute
Sponsor class: OTHER
First posted: 2024-03-12
Enrollment: 500
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: HER2 Positive Advanced Breast Cancer patients who have received Inetetamab treatment in the metastatic setting.

Brief summary: A multicenter real-world study was conducted to gather clinicopathological data from patients with HER2-positive metastatic breast cancer who were treated with inetetamab between 2022 and 2023. The study aimed to estimate the progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), and adverse events (AEs) associated with inetetamab therapy.


Eligibility criteria: Inclusion Criteria:

1. An age of at least 18 years or older
2. Pathologically diagnosed with HER2-positive recurrent or metastatic breast cancer
3. Having at least one measurable lesion as defined
4. Receiving inetetamab-based therapy in the recurrent or metastatic stage
5. Having traceable medical history records

Exclusion Criteria:

1. Pregnant or lactating women
2. Patients with other conditions deemed unsuitable for participating in this study by the researcher

Primary outcomes:
measure: Progression Free Survival(PFS)
timeFrame: 12 months
Secondary outcomes:
measure: objective response rate (ORR)
timeFrame: 12 months
measure: Adverse events (AEs)
timeFrame: 12 months
Other outcomes:
Locations:
city: Shenyang
country: China
facility: Liaoning Cancer Hospital &Institue
Study officials:
References:
Clinical trial NCT05749302: Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins
Official title: Application of Al18F-NOTA-FAPI PET/CT in Malignant Tumors Expressing Fibroblast-activated Proteins
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
PHASE3
Conditions: Malignancy
Keywords: malignant tumors expressing fibroblast-activated proteins
Lead sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Sponsor class: OTHER
First posted: 2023-03-01
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This is an open-label whole-body PET/CT study for investigating the value of Al18F-NOTA-FAPI PET/CT in patients with malignant tumors expressing fibroblast-activated proteins

Detailed description: Tumour tissue includes tumour cells as well as stromal cells (vascular cells, inflammatory cells, fibroblasts etc.). Activated fibroblasts are present not only in tumours but also in wound healing and diseases with stromal remodelling, such as chronic inflammation, myocardial infarction and liver and lung fibrosis.There is a correlation between FAP expression and tumour microvascular density and FAP expression is strongly associated with poor prognosis in a variety of tumours (e.g. colon, pancreatic, ovarian and hepatocellular carcinoma).Over 90% of FAP-positive cancer-associated fibroblasts are found in epithelial tumours, whereas fibroblasts in normal tissues rarely or even do not express FAP, making FAP a potential target for imaging and treatment of various malignancies.

Al18F-NOTA-FAPI is a posionuclide 18F-labelled tumour developer targeting FAP. Current domestic and international studies have shown that it has good stability and high FAP specificity, and shows excellent imaging quality and tumour detection in tumour-bearing mice and cancer patients, and can be used as a broad-spectrum tumour developer for clinical PET/CT imaging for diagnosis and efficacy assessment of tumour patients.

Eligibility criteria: Inclusion Criteria:

* Patients with suspected or clearly diagnosed Malignant Tumors Expressing Fibroblast-activated Proteins
* signed written consent.
* Willing and able to cooperate with all projects in this study.

Exclusion Criteria:

* pregnancy;
* breastfeeding;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Primary outcomes:
measure: Diagnostic value
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Beijing
country: China
facility: National Cancer Center/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College
state: Chao Yang
Study officials:
affiliation: National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and PUMC
name: Rong Zheng, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT02709902: Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
Official title: A Multi-center, Double-blind, Randomized, Placebo, Controlled, Parallel-group Study, Comparing Adapalene/BP Gel, 0.3%/2.5% to EPIDUO® FORTE GEL and Both Active Treatments to a Placebo Control in the Treatment of Acne Vulgaris
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Acne Vulgaris
Lead sponsor: Taro Pharmaceuticals USA
Sponsor class: INDUSTRY
First posted: 2016-03-16
Enrollment: 460
Sex: ALL
Minimum age (years): 12
Maximum age (years): 40
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Bioequivalence with Clinical Endpoints.

Detailed description: Randomized, Double-Blind, Placebo-Controlled, Multiple-Site, Parallel Design, Bioequivalence with Clinical Endpoints.

Eligibility criteria: Inclusion Criteria:

* Healthy male or non pregnant female aged ≥ 12 and ≤ 40years with a clinical diagnosis of acne vulgaris.

Exclusion Criteria:

* Female Subjects who are pregnant, nursing or planning to become pregnant during study participation

Primary outcomes:
measure: Change in inflammatory lesion counts
timeFrame: Week 12
measure: Change in non-inflammatory lesion counts
timeFrame: Week 12
Secondary outcomes:
measure: Clinical response of success
timeFrame: Week 12
Other outcomes:
Locations:
Study officials:
affiliation: http://catawbaresearch.com/contact/
name: Catawba Research
role: STUDY_CHAIR
References:
Clinical trial NCT00507702: Identification of Key Blood Molecular Markers for Immunotherapy
Official title: Identification of Key Blood Molecular Markers for Immunotherapy
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Squamous Cell Carcinoma
Adenocarcinoma
Neoplasms
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2007-07-26
Enrollment: 191
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Tumors occur predominantly in the adult population after age 30, regardless of gender and ethnic background. Therefore, our study population will consist mainly of adult subjects. We do not have any exclusion criteria based on age range, gender or ethnic background.

Brief summary: To identify unique blood markers in cancer patients so that we can identify patients with evidence of pre-existing immunity who may be a responder to immunotherapy.


Eligibility criteria: Inclusion Criteria:

1. Patients diagnosed with cancerous tumors based on biopsy or other clinical observations.
2. Patients diagnosed with non-cancerous tumors based on biopsy or other clinical observations.
3. Normal volunteers who do not have cancer or other medical conditions that may affect survival.

Exclusion Criteria:

1. Patients will be excluded if, upon clinical observation, they are under a severe septic or inflammatory condition. In these conditions, human body immune response against sepsis or inflammation should be the predominant response, and may shield or block the immune response against tumors.
2. Patients will be excluded if, upon clinical observation, they are under extremely illness situation like myocardial infarction. In such a case, the immune findings may be altered.
3. Patients will be excluded if, upon looking through their medical records, significant information required for data analysis is missing. This is because that patients' medical records will help us connect our research findings with their clinical observations, and further provide guidelines for subsequent treatment options.

Primary outcomes:
measure: To identify and evaluate the presence of pre-existing immunity related markers in peripheral human blood, to identify patients who may respond to IL-12 immunotherapy
timeFrame: 3 years
Secondary outcomes:
Other outcomes:
Locations:
city: Stanford
country: United States
facility: Stanford University School of Medicine
state: California
Study officials:
affiliation: Stanford University
name: Jeffrey A. Norton
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02933502: Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
Official title: An Open-label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use Treatment With DSXS 1538b Topical Product Applied Once-daily in Patients With Moderate to Severe Scalp Psoriasis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Scalp Psoriasis
Lead sponsor: Taro Pharmaceuticals USA
Sponsor class: INDUSTRY
First posted: 2016-10-14
Enrollment: 3
Sex: ALL
Minimum age (years): 12
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis

Detailed description: * Evaluate the potential of DSXS topical product to suppress HPA axis function in patients with moderate to severe scalp psoriasis.
* Evaluate the efficacy parameters and adverse event (AE) profiles of DSXS topical product administered to patients with moderate to severe scalp psoriasis.

Eligibility criteria: Inclusion Criteria:

* Male or non-pregnant, non-lactating females 12-17 years of age.

Exclusion Criteria:

* Females who are pregnant, nursing, planning to become pregnant during the duration of the study, or if of child-bearing potential and sexually active and not prepared to use appropriate contraceptive methods to avoid pregnancy.

Primary outcomes:
measure: Number of Participants With HPA Axis Suppression
timeFrame: day 28
Secondary outcomes:
Other outcomes:
Locations:
city: Hawthorne
country: United States
facility: Taro Pharmaceuticals USA Inc.
state: New York
Study officials:
affiliation: http://www.novumprs.com/contact
name: Novum Pharmaceutical Research Services
role: STUDY_CHAIR
References:
Clinical trial NCT00219102: A Clinical Study to Evaluate Safety & Efficacy of the Combination of Aliskiren, Valsartan & Hydrochlorothiazide in Diabetic Hypertensive Nonresponder Patients
Official title: A 12-week, Randomized, Double-blind, Placebo Controlled, Parallel Group Study Evaluating the Efficacy & Safety of Aliskiren in Patients With Diabetes & Hypertension Not Adequately Responsive to the Combination of Valsartan 160 mg & Hydrochlorothiazide 25 mg
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Hypertension
Diabetes
Keywords: Hypertension,
diabetes,
aliskiren,
blood pressure,
valsartan,
hydrochlorothiazide
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2005-09-22
Enrollment: 336
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the blood pressure lowering effect and safety of aliskiren used in combination with valsartan/hydrochlorothiazide in diabetic patients with essential hypertension, not adequately responsive to the combination of valsartan and hydrochlorothiazide


Eligibility criteria: Inclusion Criteria

* Patients with essential hypertension
* Patients with a documented diagnosis of Type 1 or Type 2 diabetes mellitus.
* Patients who are eligible and able to participate in the study

Exclusion Criteria

* Severe hypertension
* Uncontrolled diabetes type I and II
* History or evidence of a secondary form of hypertension
* History of Hypertensive encephalopathy or cerebrovascular accident.

Other protocol-defined exclusion criteria may apply.

Primary outcomes:
measure: Change from baseline in diastolic blood pressure after 12 weeks
Secondary outcomes:
measure: Change from baseline in systolic blood pressure after 12 weeks
measure: Change from baseline in systolic and diastolic blood pressure after 6 weeks
measure: Diastolic blood pressure of < 80 mmHg or a reduction from baseline of diastolic blood pressure of > 10 mmHg after 12 weeks
measure: Achieve mean sitting blood pressure control target of < 130/80 mmHg after 12 weeks
Other outcomes:
Locations:
city: Salisbury
country: United States
facility: Investigative Site
state: North Carolina
city: Kortrijk
country: Belgium
facility: Investigative Site
city: Bucharest
country: Romania
facility: Investigative Site
city: Madrid
country: Spain
facility: Investigative Site
city: Stockholm
country: Sweden
facility: Investigative Site
city: Basel
country: Switzerland
facility: Novartis Pharmaceuticals
city: Kiev
country: Ukraine
facility: Investigative Site
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_DIRECTOR
References:
citation: Drummond W, Sirenko YM, Ramos E, Baek I, Keefe DL. Aliskiren as add-on therapy in the treatment of hypertensive diabetic patients inadequately controlled with valsartan/HCT combination: a placebo-controlled study. Am J Cardiovasc Drugs. 2011 Oct 1;11(5):327-33. doi: 10.2165/11591970-000000000-00000.
Clinical trial NCT03816202: Sundt™ Carotid Shunt Retrospective Post Market Clinical Follow-up Study (PMCF)
Official title: Sundt™ Carotid Shunt Retrospective Post Market Clinical Follow-up Study (PMCF)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carotid Artery Stenosis
Lead sponsor: Integra LifeSciences Corporation
Sponsor class: INDUSTRY
First posted: 2019-01-25
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Subjects participating in the study have undergone a carotid endarterectomy procedure with the use of the Sundt™ carotid shunt prior to study initiation.

Brief summary: The primary objective of this study is to retrospectively investigate the safety and efficacy of the Integra Sundt™ carotid shunt during endarterectomy procedures.


Eligibility criteria: Inclusion Criteria:

* Between the ages of 18-80 years old
* Have undergone carotid endarterectomy with any Integra Sundt™ carotid shunt on or before date of study initiation
* Availability of records on post-operative imaging of the carotid artery either by carotid duplex ultrasound or angiogram

Exclusion Criteria:

* Insertion of a carotid shunt at the site of an infection

Primary outcomes:
measure: Evidence of Injury to the Artery or Cerebral Ischemia Secondary to Shunt Placement and Removal
timeFrame: up to 60 days post-procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Newburgh
country: United States
facility: Research Institute of Deaconess Clinic
state: Indiana
city: Hackensack
country: United States
facility: Hackensack Meridian Health
state: New Jersey
city: New York
country: United States
facility: The Mount Sinai Medical Center
state: New York
Study officials:
affiliation: Integra LifeSciences
name: Andrew Tummon
role: STUDY_DIRECTOR
References: